Skip to content
Triangle logo TriangleGet started
← Study library

NCT02663518 · REGISTRY CONDITION SEARCH

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1
Status at capture
TERMINATED
Registry last update
2024-05-10

Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

→

outcome · POSTED

Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

→

outcome · POSTED

Part 2 and 3: Number of Participants With TEAEs and TESAEs

→

outcome · POSTED

Part 4: Number of Participants With TEAEs and TESAEs

→

outcome · POSTED

Part 4: Number of Participants With Dose Limiting Toxicities (DLTs)

→

outcome · POSTED

Part 1: Maximum Plasma Concentration (Cmax) of TTI-621

→

outcome · POSTED

Part 1: Area Under the Plasma Concentration Time Curve From Time Zero to 168 (AUC[0-168]) of TTI-621

→

outcome · POSTED

Part 1: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells

→

outcome · POSTED

Part 1: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb)

→

outcome · POSTED

Part 2 and 3 Combined: Maximum Plasma Concentration (Cmax) of TTI-621

→

outcome · POSTED

Part 2 and 3 Combined: Area Under the Plasma Concentration Time Curve From Time Zero to 168 (AUC[0-168]) of TTI-621

→

outcome · POSTED

Part 2 and 3 Combined: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells

→

outcome · POSTED

Part 2 and 3: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb)

→

outcome · POSTED

Part 2 and 3: Overall Response Rate (ORR) - Lugano Classification (Cheson 2014) and Refinement (Cheson 2016) Disease Indications and Nivolumab/Rituximab Combinations

→

outcome · POSTED

Parts 2 and 3: Overall Response Rate (ORR)-Olsen 2011-Disease Indication

→

outcome · POSTED

Part 2: Overall Response Rate (ORR)-Savona 2015- Disease Indication

→

outcome · POSTED

Part 2: Overall Response Rate (ORR)- Hallek 2008- Disease Indication

→

outcome · POSTED

Part 2: Overall Response Rate (ORR)- Durie 2006- Disease Indication

→

outcome · POSTED

Part 2: Overall Response Rate (ORR)- Cheson 2003- Disease Indication

→

outcome · POSTED

Part 2: Overall Response Rate (ORR)- Bohnsack 2014- Disease Indication

→

outcome · POSTED

Parts 2 and 3: Duration of Response (DoR)- Disease Indication and Nivolumab/Rituximab Combinations

→

outcome · POSTED

Parts 2 and 3: Progression Free Survival (PFS)

→

outcome · POSTED

Part 4: Maximum Plasma Concentration (Cmax) of TTI-621

→

outcome · POSTED

Part 4: Area Under the Plasma Concentration Time Curve From Time Zero to 168 (AUC[0-168]) of TTI-621

→

outcome · POSTED

Part 4: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells

→

outcome · POSTED

Part 4: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb)

→

outcome · POSTED

Part 4: Overall Response Rate (ORR)

→

outcome · POSTED

Part 4: Duration of Response (DoR)

→

outcome · POSTED

Part 4: Overall Response Rate (ORR) in Cutaneous T-Cell Lymphoma (CTCL) Both Fungoides and Sezary Syndrome

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
MAJOR ELIGIBILITY CRITERIA: Phase 1a Escalation • Histologically documented, measurable, advanced lymphomas, transfusion-independence Phase 1b Expansion (Part 2 and 3) • Advanced malignancy: IBCL, ABCL, cHL, AML, ALL, MDS, MPN, SCLC, PTCL and CTCL; measurable disease who have relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1 prior systemic attempt for PTCL). For CTCL, extracorporeal photochemotherapy (ECP) considered a systemic therapy. Local radiation and topical agents are not systemic therapies. Phase 1b dose optimization (Part 4) • Histologically confirmed diagnosis of CTCL (both Mycosis Fungoides and Sezary Syndrome): Failed at least 2 prior systemic therapies for CTCL (Systemic therapy does not include local radiation therapy or topical agents); History of histologically documented diagnosis of CTCL stage IB to IVB Inclusion Criteria (all subjects): * Advanced measurable malignancy with previously progressed on, or currently progressing on standard anticancer therapy or for whom no other approved conventional therapy exists * Eastern Cooperative Oncology Group (ECOG) 0-2 * Adequate hematologic, hepatic, renal, and coagulation function; fresh or archived tumor tissue available for immunohistochemistry * Recovery from prior treatments and/or surgeries; no history of hemolytic anemia or bleeding diathesis. * AML M3 (French American British, FAB, classification) (i.e., acute promyelocytic leukemia \[APL\]) excluded Exclusion Criteria: * Known current central nervous system disease involvement or untreated brain metastases * Allogeneic transplant within 30 days prior to the planned start of treatment or subjects with active graft-vs-host disease with the exception of Grade 1 skin involvement * History of hemolytic anemia or bleeding diathesis
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    The Escalation Phase will include multiple doses of PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    PF-07901800 (TTI-621) Escalation Phase - R/R Lymphoma
    type
    EXPERIMENTAL
  2. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    Indolent B-Cell Lymphoma
    type
    EXPERIMENTAL
  3. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    Aggressive B-Cell Lymphoma
    type
    EXPERIMENTAL
  4. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    T-Cell Lymphoma
    type
    EXPERIMENTAL
  5. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    Hodgkin Lymphoma
    type
    EXPERIMENTAL
  6. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    Chronic Lymphocytic Leukemia
    type
    EXPERIMENTAL
  7. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    Multiple Myeloma
    type
    EXPERIMENTAL
  8. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    Acute Myeloid Leukemia
    type
    EXPERIMENTAL
  9. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    Myelodysplastic Syndrome
    type
    EXPERIMENTAL
  10. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    Myeloproliferative Neoplasms
    type
    EXPERIMENTAL
  11. description
    Monotherapy expansion cohort with PF-07901800 (TTI-621)
    intervention Names
    1. Drug: PF-0791800 (TTI-621)
    label
    Small Cell Lung Cancer
    type
    EXPERIMENTAL
  12. description
    Combination therapy expansion cohort with PF-07901800 (TTI-621) plus Rituximab for CD20 positive malignancies
    intervention Names
    1. Drug: PF-07901800 (TTI-621) plus Rituximab
    label
    Rituximab Combination
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Acute Myeloid Leukemia
    2. Aggressive B-Cell Lymphoma
    3. Chronic Lymphocytic Leukemia
    4. Cutaneous T-Cell Lymphoma (CTCL)
    5. Hodgkin Lymphoma
    6. Indolent B-Cell Lymphoma
    7. Multiple Myeloma
    8. Myelodysplastic Syndrome
    9. Myeloproliferative Neoplasms
    10. PF-07901800 (TTI-621) Escalation Phase - R/R Lymphoma
    11. Part 4: Cutaneous T-Cell Lymphoma (CTCL)
    12. Peripheral T-Cell Lymphoma (PTCL)
    description
    Monotherapy
    name
    PF-0791800 (TTI-621)
    other Names
    1. TTI-621 (SIRPα-IgG1 Fc)
    type
    DRUG
  2. arm Group Labels
    1. Rituximab Combination
    description
    Combination therapy
    name
    PF-07901800 (TTI-621) plus Rituximab
    other Names
    1. TTI-621 plus Rituxan
    type
    DRUG
  3. arm Group Labels
    1. Nivolumab Combination
    description
    Combination therapy
    name
    PF-07901800 (TTI-621) plus Nivolumab
    other Names
    1. TTI-621 plus Opdivo
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
SEQUENTIAL
intervention Model Description
Phase 1a/1b trial of PF-07901800 (TTI-621) for relapsed or refractory hematologic malignancies and selected solid tumors were conducted in 4 parts. In the dose escalation phase (Part 1), advanced lymphomas were enrolled in sequential dose cohorts for safety, tolerability, PK, and MTD. In the expansion phase (Part 2), subjects with various hematologic malignancies and selected solid tumors were treated at recommended dose determined in phase 1a (Part 1) for safety and efficacy. In the expansion phase (Part 3), 2 cohorts (cutaneous T-cell lymphoma and peripheral T-cell lymphoma) were evaluated for potentially further studied using Simon 2-stage design. In the phase 1b dose optimization (Part 4), further dose escalation was investigated in patients with relapsed and/or refractory CTCL following a 3+3 escalation and revised DLT criteria.
masking Info
masking
NONE
masking Description
Open label
primary Purpose
TREATMENT
Enrollment
count
249
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    An adverse event (AE) was any untoward medical occurrence in administered medicinal product, event need not necessarily have a causal relationship with product treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence in a participant administered a medicinal or nutritional product (including pediatric formulas) at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect. Treatment emergent AEs were events emerged during treatment period and were absent before treatment or that worsened relative to pretreatment state.
    measure
    Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
    time Frame
    Part 1: Day 1 of dosing up to 30 days of safety follow-up visit after the last dose (maximum treatment exposure for Part 1 was 414 days)
  2. description
    DLT was defined as any of the protocol specified TEAEs that occurred during the 21-day. DLT treatment/observation period (including the pre-dose tests on Day 22/Week 4 Day 1) and that were considered at least possibly related to study treatment by the investigator. Protocol specified DLT TEAE criteria: Grade 4 thrombocytopenia; Grade 3 thrombocytopenia with bleeding (with the exception of brief, easily-controlled epistaxis, mild gum bleeding or normal menses) or with any requirement for platelet transfusions; Grade 4 anemia, unexplained by underlying disease; Grade 4 neutropenia lasting more than 5 days; Febrile neutropenia of any duration ( Absolute Neutrophil Count (ANC) less than (\<) 1.0 \* 10\^9/L. fever greater than (\>) 38.5° Degree Celsius (C); Grade 3 or higher non-hematologic toxicity except for alopecia and nausea controlled by medical management; Grade 3 or 4 hemorrhage.
    measure
    Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
    time Frame
    Part 1: Day 1 of dosing up to Pre-dose on Day 22
  3. description
    An AE was any untoward medical occurrence in administered medicinal product, event need not necessarily have a causal relationship with product treatment or usage. A SAE was any untoward medical occurrence in a participant administered a medicinal or nutritional product (including pediatric formulas) at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect. Treatment emergent AEs were events emerged during treatment period and were absent before treatment or that worsened relative to pretreatment state.
    measure
    Part 2 and 3: Number of Participants With TEAEs and TESAEs
    time Frame
    Day 1 of dosing up to 30 days of safety follow-up visit after the last dose (maximum treatment exposure for Part 2 was 1793 days and for Part 3 was 938 days)
  4. description
    An AE was any untoward medical occurrence in administered medicinal product, event need not necessarily have a causal relationship with product treatment or usage. A SAE event was any untoward medical occurrence in a participant administered a medicinal or nutritional product (including pediatric formulas) at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect. Treatment emergent AEs were events emerged during treatment period and were absent before treatment or that worsened relative to pretreatment state.
    measure
    Part 4: Number of Participants With TEAEs and TESAEs
    time Frame
    Part 4: Day 1 of dosing up to 1 year of safety follow-up visit after the last dose (maximum treatment exposure for Part 4 was 667 days)
  5. description
    DLT was defined as any of the protocol specified TEAEs that occurred during the 21-day. DLT treatment/observation period (including the pre-dose tests on Day 22/Week 4 Day 1) and that were considered at least possibly related to study treatment by the investigator. Protocol specified DLT TEAE criteria: Grade 4 thrombocytopenia; Grade 3 thrombocytopenia with bleeding (with the exception of brief, easily-controlled epistaxis, mild gum bleeding or normal menses) or with any requirement for platelet transfusions; Grade 4 anemia, unexplained by underlying disease; Grade 4 neutropenia lasting more than 5 days; Febrile neutropenia of any duration (ANC \< 1.0 x 109/L, fever \> 38.5°C); Grade 3 or higher non-hematologic toxicity except for alopecia and nausea controlled by medical management; Grade 3 or 4 hemorrhage.
    measure
    Part 4: Number of Participants With Dose Limiting Toxicities (DLTs)
    time Frame
    Part 4: Day 1 of dosing up to Pre-dose on Day 22
secondary Outcomes
  1. measure
    Part 1: Maximum Plasma Concentration (Cmax) of TTI-621
    time Frame
    Part 1: Pre-dose, end of infusion (EOI), 2, 4, 24, 72, 168 hours post dose on Week 1
  2. measure
    Part 1: Area Under the Plasma Concentration Time Curve From Time Zero to 168 (AUC[0-168]) of TTI-621
    time Frame
    Part 1: Pre-dose, end of infusion (EOI), 2, 4, 24, 72, 168 hours post dose on Week 1
  3. description
    CD47 is a cell-surface protein expressed on multiple normal cell types and often at high levels on many malignant tumour cells .
    measure
    Part 1: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells
    time Frame
    Part 1: Week 1 end of infusion (EOI)
  4. description
    A participant was ADA (or NAb) positive if: (1) baseline titer was missing or negative and participants had \>1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \> \[4-fold dilution increase\] in titer from baseline in \>1 post-treatment sample (treatment-boosted).
    measure
    Part 1: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb)
    time Frame
    Part 1: From pre-infusion on day 1 up to end of study treatment (maximum treatment exposure for Part 1 was 414 days)
  5. description
    Results for this outcome measure was reported for Part 2 and Part 3 combined.
    measure
    Part 2 and 3 Combined: Maximum Plasma Concentration (Cmax) of TTI-621
    time Frame
    Part 2 and 3: Pre-dose, end of infusion (EOI), 2, 4, 24, 72, 168 hours post dose on Week 1
  6. description
    Results for this outcome measure was reported for Part 2 and Part 3 combined.
    measure
    Part 2 and 3 Combined: Area Under the Plasma Concentration Time Curve From Time Zero to 168 (AUC[0-168]) of TTI-621
    time Frame
    Part 2 and 3: Pre-dose, end of infusion (EOI), 2, 4, 24, 72, 168 hours post dose on Week 1
  7. description
    CD47 is a cell-surface protein expressed on multiple normal cell types and often at high levels on many malignant tumour cells. Results are reported for combined Part 2 and 3.
    measure
    Part 2 and 3 Combined: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells
    time Frame
    Part 2 and 3: Week 1 end of infusion (EOI)
  8. description
    A participant was ADA (or NAb) positive if: (1) baseline titer was missing or negative and participants had \>1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \> 4-fold dilution increase in titer from baseline in \> 1 post-treatment sample (treatment-boosted).
    measure
    Part 2 and 3: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb)
    time Frame
    Part 2 and 3: From pre-infusion on day 1 up to end of study treatment (maximum treatment exposure for Part 2 was 1793 days and for Part 3 was 938 days)
  9. description
    ORR is presented in this outcome measure as number of responders. Responders were those who had complete remission and partial remission. Lugano classification (Cheson et al., 2014) and refinement (Cheson et al., 2016) were used for tumor response assessment for lymphomas by computed tomography (CT)-based criteria and complete metabolic response (CMR) or partial metabolic response (PMR) by positron emission tomography (PET-CT) based criteria were used for evaluation. Lymphomas evaluated by Lugano Classification include aggressive B-cell lymphoma (ABCL), Hodgkin's lymphoma (HL), Non-Hodgkin's lymphoma, indolent B-cell lymphoma (IBCL), peripheral T-cell lymphoma (PTCL), and part of T-cell lymphoma (TCL).
    measure
    Part 2 and 3: Overall Response Rate (ORR) - Lugano Classification (Cheson 2014) and Refinement (Cheson 2016) Disease Indications and Nivolumab/Rituximab Combinations
    time Frame
    From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)
  10. description
    ORR is presented in this outcome measure as number of responders. Responders were those who had complete response and partial response. Clinical endpoints and response criteria (Olsen et al., 2011) for in CTCL (mycosis fungoides and Sezary syndrome) and TCL were used for assessment. Tumor types evaluated included Cutaneous T-cell lymphoma (CTCL) and a part of T-cell lymphoma (TCL).
    measure
    Parts 2 and 3: Overall Response Rate (ORR)-Olsen 2011-Disease Indication
    time Frame
    From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)
  11. description
    ORR is presented in this outcome measure as number of responders. Responders were those who had complete remission, partial remission and marrow response. International Consortium Proposal of Uniform Response Criteria for Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) in adults (Savona et al., 2015) was used for assessment of tumors. Tumor types evaluated include Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
    measure
    Part 2: Overall Response Rate (ORR)-Savona 2015- Disease Indication
    time Frame
    From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)
  12. description
    ORR is presented in this outcome measure as number of responders. Responders were those who had complete response or complete remission, complete response or complete remission with incomplete marrow recovery, partial response. International Workshop on CLL update of the NCI 1996 Guidelines (Hallek et al., 2008) was used for assessment of tumors. Tumor types evaluated include chronic lymphocytic leukemia (CLL).
    measure
    Part 2: Overall Response Rate (ORR)- Hallek 2008- Disease Indication
    time Frame
    From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)
Full study description
brief Summary
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
detailed Description
This is a trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors. TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory "do not eat" (anti phagocytic) signal to macrophages. This trial will be conducted in 2 phases and 4 parts: Phase 1a Part 1 (escalation phase) and Phase 1b Parts 2-4 (expansion phase). In the dose Escalation Phase (phase 1a Part 1), subjects with lymphoma will be enrolled in sequential dose cohorts to receive TTI-621 to characterize safety, tolerability, pharmacokinetics, and the maximum-tolerated dose (MTD). In the Expansion Phase (phase 1b Parts 2-4), TTI-621 will be given to subjects with a variety of hematologic malignancies and selected solid tumors to further define safety and to characterize efficacy. In the Expansion Phase Part 2, the safety and efficacy of TTI-621 will also be assessed when it is given in combination with other anti-cancer drugs. The dose of TTI-621 to be delivered in the Expansion Phase Parts 2-3 of the study may be increased or decreased based on the subject's tolerability and on the subject's response to treatment. In the phase 1b dose optimization of the study (Part 4), further dose escalation of TTI-621, beyond the dose determined during phase 1a dose escalation, will be pursued in patients with relapsed and/or refractory CTCL following a 3+3 escalation design and using a revised DLT criteria to further evaluate the safety and tolerability of TTI-621 at dose levels higher than the initially recommended phase 1b Parts 2-3. Secondary objectives include further characterization of the pharmacokinetics, pharmacodynamics, and development of ADA; and to gain preliminary evidence of the anti-tumor activity of TTI-621 in subjects with a variety of hematologic malignancies and selected solid tumors. In addition, the safety of TTI-621 will be evaluated in combination with other anti-cancer agents. Pfizer decided terminating this study for administrative reasons on 22Mar2022 (stopping enrollment as of 15Apr2022). The decision wasn't due to safety concerns or requests from regulatory authorities.
Source references
references
  1. citation
    Marks JA, Wang X, Fenu EM, Bagg A, Lai C. TP53 in AML and MDS: The new (old) kid on the block. Blood Rev. 2023 Jul;60:101055. doi: 10.1016/j.blre.2023.101055. Epub 2023 Feb 14.
    pmid
    36841672
    type
    DERIVED
  2. citation
    Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, Minden MD, Villa D, Percival MM, Advani AS, Foran JM, Horwitz SM, Mei MG, Zain J, Savage KJ, Querfeld C, Akilov OE, Johnson LDS, Catalano T, Petrova PS, Uger RA, Sievers EL, Milea A, Roberge K, Shou Y, O'Connor OA. Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clin Cancer Res. 2021 Apr 15;27(8):2190-2199. doi: 10.1158/1078-0432.CCR-20-3706. Epub 2021 Jan 15.
    pmid
    33451977
    type
    DERIVED
  3. citation
    Johnson LDS, Banerjee S, Kruglov O, Viller NN, Horwitz SM, Lesokhin A, Zain J, Querfeld C, Chen R, Okada C, Sawas A, O'Connor OA, Sievers EL, Shou Y, Uger RA, Wong M, Akilov OE. Targeting CD47 in Sezary syndrome with SIRPalphaFc. Blood Adv. 2019 Apr 9;3(7):1145-1153. doi: 10.1182/bloodadvances.2018030577.
    pmid
    30962222
    type
    DERIVED
see Also Links
  1. label
    To obtain contact information for a study center near you, click here.
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-0469b6d537cd57a71ff5
      requested nct id
      NCT02663518
      primary nct id
      NCT02663518
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      3bc8ebf7c98bbd021dc781b00e5208a64530695e71a9bb6518665c77a67a769e
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-0469b6d537cd57a71ff5
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02663518
      occurrences
      1. context exact
        NCT02663518
        end
        11
        exact text
        NCT02663518
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/831/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6317b87a8fab8443149221e4351d78af4023f6b8ecc50323a243aaf257654eef
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-31171cd96041a8c95b14
      requested nct id
      NCT02663518
      primary nct id
      NCT02663518
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      aed04ce567b94d2e7b318399d703b798c8b6daa84376c4f908c6b9504e8aab9d
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-31171cd96041a8c95b14
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02663518
      occurrences
      1. context exact
        NCT02663518
        end
        11
        exact text
        NCT02663518
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/111/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6317b87a8fab8443149221e4351d78af4023f6b8ecc50323a243aaf257654eef

    Preserved source evidence · Not medical advice